Shares of Sucampo Pharmaceuticals soared 24% as the company received an expanded indication for Amitiza, which is now the only FDA-approved oral medication for constipation from taking opioid painkillers for non-cancer pain.
In this video, health-care analyst David Williamson explains what this means for Sucampo and why, despite the size of the market, investors may not want to rush in and grab shares after today's big pop.
Moving from the micro of a single stock pop like Sucampo's to broader macro issues, Warren Buffett described an important trend as "the tapeworm that's eating at American competitiveness" Find out what he meant in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.